HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gold, J. S. Articles by Houghton, A. N. Search for Related Content PubMed PubMed Citation Articles by Gold, J. S. Articles by Houghton, A. N. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-TRYPTOPHAN

A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen¹

Jason S. Gold^*, Cristina R. Ferrone^*, Jose A. Guevara-Patiño^*, William G. Hawkins^*, Ruben Dyall^*, Manuel E. Engelhorn^*, Jedd D. Wolchok^*,, Jonathan J. Lewis^*, and Alan N. Houghton^2,*,

^* Memorial Sloan-Kettering Cancer Center and Weill Medical School and Graduate School of Medical Sciences, Cornell University, New York, NY 10021

Successful active immunization against cancer requires induction of immunity against self or mutated self Ags. However, immunization against self Ags is difficult. Xenogeneic immunization with orthologous Ags induces cancer immunity. The present study evaluated the basis for immunity induced by active immunization against a melanoma differentiation Ag, gp100. Tumor rejection of melanoma was assessed after immunization with human gp100 (hgp100) DNA compared with mouse gp100 (mgp100). C57BL/6 mice immunized with xenogeneic full-length hgp100 DNA were protected against syngeneic melanoma challenge. In contrast, mice immunized with hgp100 DNA and given i.p. tolerizing doses of the hgp100 D^b-restricted peptide, hgp100_25–33, were incapable of rejecting tumors. Furthermore, mice immunized with DNA constructs of hgp100 in which the hgp100_25–27 epitope was substituted with the weaker D^b-binding epitope from mgp100 (mgp100_25–27) or a mutated epitope unable to bind D^b did not reject B16 melanoma. Mice immunized with a minigene construct of hgp100_25–33 rejected B16 melanoma, whereas mice immunized with the mgp100_25–33 minigene did not develop protective tumor immunity. In this model of xenogeneic DNA immunization, the presence of an hgp100 heteroclitic epitope with a higher affinity for MHC created by three amino acid (25 to 27) substitutions at predicted minor anchor residues was necessary and sufficient to induce protective tumor immunity in H-2^b mice with melanoma.

This article has been cited by other articles:

				G. A. Rizzuto, T. Merghoub, D. Hirschhorn-Cymerman, C. Liu, A. M. Lesokhin, D. Sahawneh, H. Zhong, K. S. Panageas, M.-A. Perales, G. Altan-Bonnet, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response J. Exp. Med., April 13, 2009; 206(4): 849 - 866. [Abstract] [Full Text] [PDF]

				Y. M. Saenger, Y. Li, K. C. Chiou, B. Chan, G. Rizzuto, S. L. Terzulli, T. Merghoub, A. N. Houghton, and J. D. Wolchok Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma Cancer Res., December 1, 2008; 68(23): 9884 - 9891. [Abstract] [Full Text] [PDF]

				M. Wuttke, C. Papewalis, Y. Meyer, C. Kessler, B. Jacobs, H. S. Willenberg, S. Schinner, C. Kouatchoua, T. Baehring, W. A. Scherbaum, et al. Amino Acid-Modified Calcitonin Immunization Induces Tumor Epitope-Specific Immunity in a Transgenic Mouse Model for Medullary Thyroid Carcinoma Endocrinology, November 1, 2008; 149(11): 5627 - 5634. [Abstract] [Full Text] [PDF]

				C. Papewalis, M. Wuttke, J. Seissler, Y. Meyer, C. Kessler, B. Jacobs, E. Ullrich, H. S. Willenberg, S. Schinner, T. Baehring, et al. Dendritic Cell Vaccination with Xenogenic Polypeptide Hormone Induces Tumor Rejection in Neuroendocrine Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4298 - 4305. [Abstract] [Full Text] [PDF]

				K. Kianizad, L. A. Marshall, N. Grinshtein, D. Bernard, R. Margl, S. Cheng, F. Beermann, Y. Wan, and J. Bramson Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope Cancer Res., July 1, 2007; 67(13): 6459 - 6467. [Abstract] [Full Text] [PDF]

				C. R. Ferrone, M.-A. Perales, S. M. Goldberg, C. J. Somberg, D. Hirschhorn-Cymerman, P. D. Gregor, M. J. Turk, T. Ramirez-Montagut, J. S. Gold, A. N. Houghton, et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin fc domains. Clin. Cancer Res., September 15, 2006; 12(18): 5511 - 5519. [Abstract] [Full Text] [PDF]

				S. Colombetti, T. Fagerberg, P. Baumgartner, L. Chapatte, D. E. Speiser, N. Rufer, O. Michielin, and F. Levy Impact of Orthologous Melan-A Peptide Immunizations on the Anti-Self Melan-A/HLA-A2 T Cell Cross-Reactivity. J. Immunol., June 1, 2006; 176(11): 6560 - 6567. [Abstract] [Full Text] [PDF]

				A. D. Cohen, A. Diab, M.-A. Perales, J. D. Wolchok, G. Rizzuto, T. Merghoub, D. Huggins, C. Liu, M. J. Turk, N. P. Restifo, et al. Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. Cancer Res., May 1, 2006; 66(9): 4904 - 4912. [Abstract] [Full Text] [PDF]

				S. M. Goldberg, S. M. Bartido, J. P. Gardner, J. A. Guevara-Patino, S. C. Montgomery, M.-A. Perales, M. F. Maughan, J. Dempsey, G. P. Donovan, W. C. Olson, et al. Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles Clin. Cancer Res., November 15, 2005; 11(22): 8114 - 8121. [Abstract] [Full Text] [PDF]

				K. Kawano, C. L. Efferson, G. E. Peoples, D. Carter, N. Tsuda, J. L. Murray, and C. G. Ioannides Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death Cancer Res., April 1, 2005; 65(7): 2930 - 2937. [Abstract] [Full Text] [PDF]

				M. L. Palomba, W. K. Roberts, T. Dao, G. Manukian, J. A. Guevara-Patino, J. D. Wolchok, D. A. Scheinberg, and A. N. Houghton CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma Clin. Cancer Res., January 1, 2005; 11(1): 370 - 379. [Abstract] [Full Text] [PDF]

				D. W. O'Neill, S. Adams, and N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood, October 15, 2004; 104(8): 2235 - 2246. [Abstract] [Full Text] [PDF]

				M. J. Turk, J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn, and A. N. Houghton Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells J. Exp. Med., September 20, 2004; 200(6): 771 - 782. [Abstract] [Full Text] [PDF]

				A. I. Webb, M. A. Dunstone, W. Chen, M.-I. Aguilar, Q. Chen, H. Jackson, L. Chang, L. Kjer-Nielsen, T. Beddoe, J. McCluskey, et al. Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue J. Biol. Chem., May 28, 2004; 279(22): 23438 - 23446. [Abstract] [Full Text] [PDF]

				C. Lane, J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin Cancer Res., February 15, 2004; 64(4): 1509 - 1514. [Abstract] [Full Text] [PDF]

				W. W. Overwijk, M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells J. Exp. Med., August 18, 2003; 198(4): 569 - 580. [Abstract] [Full Text] [PDF]